NCT07213804 2026-03-20
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
13 trialsNCT01012817 2025-09-15
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04514497 2025-03-06
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01703910 2015-10-09
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 2 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00541138 2011-09-21
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
City of Hope Medical Center
Phase 2 Completed
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed
NCT00252889 2009-01-27
Doxil Topotecan Doublet Cancer Study
Christiana Care Health Services
Phase 1 Completed